Study objective
Anxiety, Pain, cancer pain, pain, chronic pain, Depression, NRS
RESIDUAL, SECONDARY, CHRONIC PAIN, CORTEX
This study is designed to evaluate the analgesic efficacy of 5 consecutive tDCS sessions to the primary motor cortex in patients with cancer pain in the palliative care setting.The primary endpoint is the score of the numerical rating scale (NRS), which measures pain intensity on a scale from 0 to 10 [The secondary objectives will be to evaluate:Immediate impact of each tDCS session on pain intensity.Response rate at the end of treatment.Residual analgesic effect.Effects of TDCS on the other main symptoms likely to impair quality of life.Analgesic consumption on D0 and D8.Secondary endpoints will be:Pain NRS score, MQS (Medication Quantification Scale [Pain NRS scores, recorded before and after each session.Efficacy of treatment, defined by a ≥ 20% reduction of the mean NRS score between D0 and D8 (IMMPACT recommendation in chronic pain [Mean NRS score on D14 and D21 in the 2 arms.Completion of the following questionnaires and scales on D0 and D8:. BPI (Brief Pain Inventory, short form [. ESAS (Edmonton Symptom Assessment System) [. HADS (Hospital Anxiety and Depression Scale) [. STAI-Y (State-Trait Anxiety Inventory (Form Y) [Analgesic consumption assessed by MQS on D0 and D8.Analysis of repeated measurements of quantitative secondary endpoints (NRS, BPI, ESAS, HADS, STAI-Y and MQS) will be based on the mean variations of the endpoint between the baseline assessment (D0) and the D21 assessment.